Condition: Bronchiolitis Obliterans Syndrome (BOS) · Bronchiolitis Obliterans (BO) · Sponsor: University Hospital, Basel, Switzerland
This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation. All study patients with BOS will be treated with the study drug Nintedanib (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months treatment period.
This description comes directly from the study's public registry record.
Katrin Hostettler Haack, PD Dr. med · +41 61 328 69 16 · Katrin.Hostettler@usb.ch
Sandra Kunze · +41 61 328 55 10 · Sandra.Kunze@usb.ch
Always discuss trial participation with your own doctor first.
| King Faisal Specialist Hospital & Research Centre | Riyadh, Saudi Arabia | Recruiting |
| Clinic of Hematology, University Hospital Basel | Basel, Switzerland | Recruiting |
| Clinic of Respiratory Medicine, University Hospital Basel | Basel, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03805477